Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Sarah C. Rutherford"'
Autor:
David Qualls, Michael J Buege, Phuong Dao, Paolo F. Caimi, Sarah C. Rutherford, Graham Wehmeyer, Jason T. Romancik, Lori A. Leslie, Mwanasha H. Merrill, Jennifer L. Crombie, Behzad Amoozgar, Brad S. Kahl, David A. Bond, Kami J. Maddocks, Michelle Okwali, Venkatraman Seshan, Gilles Salles, Connie Lee Batlevi
Publikováno v:
Blood. 140:787-789
Autor:
Muhammad Saad Hamid, Sarah C. Rutherford, Hyejeong Jang, Seongho Kim, Krish Patel, Nancy L. Bartlett, Mary-Kate Malecek, Marcus P. Watkins, Kami J. Maddocks, David A. Bond, Tatyana A. Feldman, Gabriela Magarelli, Ranjana H Advani, Michael A Spinner, Andrew M. Evens, Mansi Shah, Sairah Ahmed, Deborah M. Stephens, Pamela Allen, Michael T. Tees, Reem Karmali, Bruce D. Cheson, Maryam Sarraf Yazdy, Christopher Strouse, Neil A. Bailey, John M. Pagel, Radhakrishnan Ramchandren
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:e435-e442
The utility of dose escalation after positive positron emission tomography following 2 cycles of ABVD (PET2) for Hodgkin Lymphoma (HL) remains controversial. We describe the United States real-world practice patterns for PET2 positive patients.Data w
Autor:
Jia Ruan, Alison J Moskowitz, Neha Mehta-Shah, Lubomir Sokol, Zhengming Chen, Nikita Kotlov, Grigorii Nos, Maria Sorokina, Vladislav Maksimov, Andrea Sboner, Michael Sigouros, Koen van Besien, Steven M Horwitz, Sarah C. Rutherford, Erin Mulvey, María V. Revuelta, Jenny Z Xiang, Alicia Alonso, Ari M. Melnick, Olivier Elemento, Giorgio GA Inghirami, John P. Leonard, Leandro Cerchietti, Peter Martin
Publikováno v:
Blood.
PTCL with T-follicular helper phenotype (PTCL-TFH) has recurrent mutations affecting epigenetic regulators, which may contribute to aberrant DNA methylation and chemoresistance. This phase 2 study evaluated oral azacitidine (CC-486), a DNA methyltran
Autor:
Katharina Lechner, Izolda Franjkovic, Emily Labriola-Tompkins, Martin Hutchings, Jurriaan Brouwer-Visser, Mark DeMario, Alex F. Herrera, Javier Briones, Eirini Bournazou, Eveline Nüesch, Michael Dickinson, Dominik Rüttinger, Nilanjan Ghosh, Sarah C. Rutherford, Barbara J. Brennan, Martin Kornacker, Evelyne Chesne, Raul Cordoba, Eva González-Barca
Publikováno v:
Blood Advances
Key Points BET inhibitor RO6870810+venetoclax+rituximab has a manageable safety profile in relapsed/refractory diffuse large B-cell lymphoma.A clinically relevant signal of antitumor activity serves as a proof of principle for this combination, warra
Autor:
Nadia Khan, Stefan K. Barta, Ying Yuan, Robin Joyce, Jason R. Westin, Sarah C. Rutherford, Silvia Senese, Jeremy S. Abramson, Nancy L. Bartlett, Trisha Ali-Shaw, John P. Leonard, Kami J. Maddocks
Publikováno v:
The Lancet Haematology. 8:e818-e827
Background Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) is a front-line treatment for patients with aggressive B-cell lymphomas. Bcl-2 is associated with chemoresistance due to BCL2 gene rea
Autor:
Jordan Ciuro, Elizabeth Henry, Nadine Housri, Rahul Banerjee, Elizabeth A Brem, Taylor Brooks, Ben A. Derman, Brian T. Hill, Craig C Hofmeister, Matthew A. Lunning, Matthew J. Matasar, Tycel J. Phillips, Sarah C. Rutherford, Saurabh Zanwar, Lauren E Lee
Publikováno v:
Blood. 140:13180-13181
Autor:
Sarah C. Rutherford, John P. Leonard, Chrystal Marte, Kelly M. Trevino, Login S. George, Daniel Jie Ouyang, Peter Martin
Publikováno v:
Palliat Support Care
ContextExisting research on psychological distress and mental health service utilization has focused on common types of solid tumor cancers, leaving significant gaps in our understanding of patients experiencing rare forms of hematologic cancers.Obje
Autor:
Adomah Opong, June Greenberg, Richard R. Furman, Adriana C Rossi, Michelle Pasciolla, Koen van Besien, Adrienne A. Phillips, Yuliya S. Jhanwar, Usama Gergis, Tsiporah B. Shore, Peter Martin, Tomer M Mark, John P. Leonard, Grace Suhu, Sarah C. Rutherford, Kathleen Maignan, Sebastian Mayer, Jessy Ryan, Danielle Guarneri, Roger N. Pearse, Calvin Koo, Jia Ruan, Maria Baldo, Jingmei Hsu, Edwidge Cuvilly, Nina Orfali
Publikováno v:
Leukemia & Lymphoma. 62:1629-1638
We evaluate the safety of bendamustine as a bridge to stem cell transplantation (SCT) in patients with relapsed/refractory lymphoma and residual disease after salvage therapy. Thirty-four subjects without complete responses (CR) received bendamustine
Autor:
Daniel Jie Ouyang, John P. Leonard, Sarah C. Rutherford, Chrystal Marte, Kelly M. Trevino, Holly G. Prigerson, Peter Martin
Publikováno v:
J Palliat Med
Background: The prognosis of an aggressive lymphoma can change dramatically following failure of first-line treatment. This sudden shift is challenging for the promotion of illness understanding and advance care planning (ACP). Yet, little is known a
Autor:
Federico Mattiello, Marek Trněný, Robert Marcus, Umberto Vitolo, Maurizio Martelli, Michael Herold, L. Kostakoglu, Judith Trotman, Sarah C. Rutherford, Wolfgang Hiddemann, Gila Sellam, Deniz Sahin, Tina Nielsen, Laurie H. Sehn, Peter Martin
Publikováno v:
Blood Advances. 4:1589-1593
The utility of posttreatment bone marrow biopsy (BMB) histology to confirm complete response (CR) in lymphoma clinical trials is in question. We retrospectively evaluated the impact of BMB on response assessment in immunochemotherapy-treated patients